Core Insights - 博锐生物 is preparing for an IPO on the Hong Kong Stock Exchange, showing consistent revenue growth in recent years but a declining gross margin [1] Financial Performance - Revenue for 2023 and 2024 is projected at 1.257 billion and 1.623 billion respectively, with operating profits of 61.65 million and 158 million, and net profits of 19.01 million and 91.3 million [1] - For the first nine months of 2025, revenue reached 1.379 billion with a net profit of 122 million [1] - Gross margins have declined from 82.2% in 2023 to 74.4% in the first nine months of 2025, a total decrease of 7.8 percentage points [1] - Adjusted net margins have increased from 2.5% in 2023 to 11.3% in the first nine months of 2025, indicating effective cost control and expense management [2] Customer and Supplier Concentration - The company has a high customer concentration, with revenue from the top five customers accounting for over 60% of total revenue in recent years [2][3] - The largest customer contributed 28.2%, 32.3%, and 27.7% of revenue in 2023, 2024, and the first nine months of 2025 respectively [2] - Supplier concentration is also high, with the top five suppliers accounting for 30.4%, 34.1%, and 46.0% of total purchases in the same periods [3] Related Party Transactions - 博锐生物 has multiple related party transactions with its controlling shareholder, 海正药业, including asset leasing and technical services, with rental expenses of 2.8 million and 3.2 million for 2023 and 2024 respectively [2] - The company has applied for and received a three-year exemption from the Hong Kong Stock Exchange regarding certain related party transaction approvals [2]

Group 1 - The Ministry of Commerce of China has decided to strengthen export controls on dual-use items to Japan, prohibiting all dual-use items from being exported to military users and any end-users that could enhance Japan's military capabilities [2][45][46] - China is considering tightening the export license review for medium and heavy rare earth items to Japan, which will be implemented starting April 4, 2025, under the Export Control Law [3][47] - China's Foreign Ministry has warned that Japan's recent moves towards militarization, including revising security documents to increase defense spending and develop offensive military capabilities, pose a danger to regional peace [4][48] Group 2 - The People's Bank of China has outlined seven key priorities for 2026, emphasizing the importance of monetary policy in promoting high-quality economic development and price stability, with a flexible approach to using tools like interest rate cuts [8][51] - A significant increase in new A-share accounts was reported, with 2.74369 million new accounts opened in 2025, marking a 9.75% year-on-year growth and the highest annual figure since 2022 [9][52][53] - The Shanghai Composite Index achieved a record 13 consecutive positive trading days, marking the longest streak in its history, with a 1.5% increase on January 6 [9][53] Group 3 - Financial regulators are conducting research to address barriers to long-term capital entering the market, focusing on enhancing the investment scale and proportion of bank wealth management products in A-shares [10][54] - The commercial aerospace sector continues to show strong growth potential, with expectations of a turning point in the industry [16][60] - The lithium carbonate market is experiencing a significant price increase at the start of the year due to tight supply and demand conditions [16][60]

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. announced that its subsidiary, Zhejiang Borui Biopharmaceutical Co., Ltd., has submitted an application for an initial public offering (IPO) of H-shares to the Hong Kong Stock Exchange on January 6, 2026 [1][2]. Group 1: Company Overview - Borui Biopharmaceutical is a leading biopharmaceutical company in China focused on immunotherapy, with integrated capabilities in research, production, and sales [2]. - The company aims to provide comprehensive immunotherapy solutions for patients with autoimmune diseases, inflammatory diseases, tumor immunology diseases, and malignancies caused by immune system disorders [2]. - Borui Biopharmaceutical has established a competitive portfolio of immunotherapy products, including eight commercialized products and several innovative drug candidates in development [2]. Group 2: Market Position - According to Frost & Sullivan, Borui Biopharmaceutical has ranked first in market share in the biopharmaceutical sector for autoimmune diseases in China based on sales revenue for two consecutive years starting in 2023 [2]. - The company holds a 39.62% stake in Borui Biopharmaceutical as of the date of the announcement [2]. Group 3: Regulatory Approval - The IPO application is subject to approval from the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange, indicating that there is uncertainty regarding the outcome [3]. - The application materials submitted are in draft form and may be updated or changed as required by regulatory authorities [2][3].

Group 1: Company Updates - ChaoYing Electronics has adjusted the investment amount for its AI computing power high-end printed circuit board expansion project from 1.468 billion RMB to 3.315 billion RMB, aiming to meet stronger demand for high-end PCB products and enhance overseas production capabilities [2] - Baihua Pharmaceutical and Siwei Control have both terminated their plans for control change due to a lack of consensus with the transaction parties, with their stocks set to resume trading on January 7, 2026 [3] - Aihui Long has signed a strategic cooperation framework agreement with Brain Machine Star Chain to enhance market expansion and sales of brain-machine interface products through its strong sales channels in emergency, brain disease diagnosis, and pediatrics [10] Group 2: Performance Forecasts - Zhongtai Co. expects a net profit of 420 million to 480 million RMB for 2025, recovering from a loss of 77.96 million RMB in the previous year due to improved operations of its subsidiary [5] - Lier Chemical anticipates a net profit of 460 million to 500 million RMB for 2025, representing a year-on-year growth of 113.62% to 132.19% due to increased demand for its products [5] Group 3: Financing and Restructuring - Zhejiang Xiantong plans to issue A-shares to no more than 35 specific investors, raising up to 1.05 billion RMB for smart manufacturing projects and working capital [7] - Longjing Environmental Protection has received acceptance from the Shanghai Stock Exchange for its securities issuance application, pending further approvals [8] Group 4: Strategic Partnerships - Fushite has signed a strategic cooperation agreement with Jiangxi Copper Group to enhance collaboration in mining equipment maintenance and expand overseas market development [15] - Pro Pharmaceutical has entered into a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., focusing on long-term collaboration in innovative drug research and outsourced production [15] Group 5: Market Activity and Stock Performance - Jia Mei Packaging's stock price increased by 230.48% from December 17, 2025, to January 6, 2026, prompting a temporary suspension for investigation due to significant price volatility [11] - Guosheng Technology's stock experienced a 370.20% increase from October 31, 2025, to January 6, 2026, leading to a suspension for review due to potential irrational market behavior [20]

Company Overview - Zhejiang BoRui Biopharmaceutical Co., Ltd. is a leading integrated biopharmaceutical company in China, focusing on providing comprehensive immunotherapy solutions for patients with autoimmune and inflammatory diseases, as well as tumor immunology diseases [3] - The company has ranked first among Chinese pharmaceutical companies in terms of revenue from biological agents for autoimmune diseases for two consecutive years starting in 2023, according to Frost & Sullivan [3] - BoRui Biopharmaceutical strategically focuses on immunotherapy, utilizing immune science to regulate immune function and address diseases where immune dysregulation plays a critical role [3] Product Portfolio - The innovative product lineup includes the first-in-class IL-17A/F inhibitor Beijiele (Bicizumab), China's first and only innovative CD20 monoclonal antibody Anruixi (Zebetomab), and BR2251, a potential first-in-class gout drug with a differentiated mechanism of action [4] - The company has established one of the most competitive and comprehensive immunological product portfolios in the industry, supported by eight commercialized products and a pipeline of innovative candidates [4] Financial Performance - For the fiscal years ending December 31, 2023, 2024, and the nine months ending September 30, 2025, the company reported revenues of approximately RMB 1.257 billion, RMB 1.623 billion, and RMB 1.379 billion, respectively [5] - The profit attributable to equity shareholders for the same periods was RMB 19.01 million, RMB 91.30 million, and RMB 121.84 million, respectively [6] - The gross profit margins for the fiscal years were 82.2%, 79.2%, and 74.4% [8] Industry Overview - The autoimmune disease market is one of the fastest-growing sectors in the global pharmaceutical market, with a projected compound annual growth rate (CAGR) of 21.9%, expanding from RMB 174 billion in 2020 to RMB 328 billion by 2024, and expected to reach RMB 2,899 billion by 2035 [10] - The market for biological agents in autoimmune diseases is also rapidly expanding, with a CAGR of 42.5%, expected to grow from RMB 42 billion in 2020 to RMB 171 billion by 2024, and projected to reach RMB 2,126 billion by 2035 [10] - The tumor immunology market is anticipated to grow from RMB 148 billion in 2020 to RMB 293 billion by 2024, with a CAGR of 18.5%, and is expected to further expand to RMB 4,954 billion by 2035, driven by the approval of innovative therapies [13] Shareholding Structure - As of December 29, 2025, the company's equity is held by PAG Highlander and Haizheng Pharmaceutical, owning 44.62% and 39.62% of the shares, respectively [21]

Core Viewpoint - Haizheng Pharmaceutical (600267) announced that its associate company, Zhejiang Borui Biopharmaceutical Co., Ltd. (Borui Biopharma), has submitted an application for an initial public offering (IPO) of H-shares on the Hong Kong Stock Exchange on January 6 [2]. Group 1 - Haizheng Pharmaceutical holds a 39.62% stake in Borui Biopharma as of the announcement date [2]. - The IPO application materials were published on the Hong Kong Stock Exchange website on the same day [2].

Group 1 - The core point of the article is that Zhejiang BoRui Biopharmaceutical Co., Ltd. has submitted an application for an initial public offering (IPO) of overseas listed shares (H shares) to the Hong Kong Stock Exchange, aiming for a listing on January 6, 2026 [1] - BoRui Biopharmaceutical is a leading biopharmaceutical company in China focused on immunotherapy, with integrated capabilities in research, production, and sales [1] - The company aims to provide comprehensive immunotherapy solutions for patients with autoimmune diseases, inflammatory diseases, tumor immunology diseases, and malignancies caused by immune system disorders [1] Group 2 - As of the announcement date, the company holds a 39.62% stake in BoRui Biopharmaceutical [1]

Group 1 - Company Zhejiang Borui Biopharmaceutical Co., Ltd. has submitted an application for an initial public offering (IPO) of overseas listed shares (H shares) to the Hong Kong Stock Exchange on January 6, 2026 [1] - Borui Biopharmaceutical is a leading biopharmaceutical company in China focused on immunotherapy, with integrated capabilities in research, production, and sales [2] - The company has developed a competitive portfolio of immunotherapy products, including the globally first-in-class IL-17A/F inhibitor Beijiele® and the first and only approved targeted CD20 innovative drug Anruixi® [2] Group 2 - Borui Biopharmaceutical has ranked first in the market share of biopharmaceuticals in the field of autoimmune diseases in China for two consecutive years since 2023, based on sales data [2] - The company holds a 39.62% stake in Borui Biopharmaceutical as of the date of the announcement [2]

证券代码：600267 证券简称：海正药业 公告编号：临 2026-04 号 浙江海正药业股份有限公司 博锐生物是国内领先的聚焦免疫疗法的生物制药公司，具备研产销综合一体 化能力。自成立以来，博锐生物始终致力于为自身免疫类疾病、炎症类疾病、肿 瘤免疫类疾病以及免疫系统失调导致的恶性肿瘤类疾病的患者提供全面的免疫 治疗方案。博锐生物已经建立了具有竞争力的免疫产品组合：包括截至目前全球 同类首创、同适应症疗效更优的IL-17A/F抑制剂倍捷乐®（比奇珠单抗），中国 首款且唯一获批靶向CD20的一类创新药安瑞昔®（泽贝妥单抗）等八款已商业化 产品，BR2251（一款拥有差异化作用机制，具有同类首创潜力的在研痛风药物）， 以及基于两大下一代ADC技术平台孵化的多款在研创新ADC管线。根据弗若斯 特沙利文的统计，在涉足自身免疫疾病领域的中国医药企业中，博锐生物按销售 额统计已自2023年起连续两年排名生物制剂市场份额第一。截至本公告披露日， 公司持有博锐生物39.62%的股份。 博锐生物本次递交的申请资料系按照香港证券及期货事务监察委员会及香 港联交所的要求编制和刊发，为草拟版本，其所载资料可能会适时作出更新和变 动。 ...

人民财讯1月6日电，海正药业（600267）1月6日公告，公司从参股子公司浙江博锐生物制药股份有限公 司(简称"博锐生物")处获悉，博锐生物已于2026年1月6日向香港联交所递交了首次公开发行境外上市股 份(H股)并在香港联交所主板上市的申请，并于同日在香港联交所网站刊登了本次发行的申请资料。截 至本公告披露日，公司持有博锐生物39.62%的股份。 ...